XPO1抗体;XPO1 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: HEPG2 and Hela cell lysates, Primary antibody: P13157(XPO1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13157(XPO1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P13157(XPO1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

XPO1 (Exportin 1), also known as CRM1. is a nuclear export protein responsible for transporting cargo molecules, including tumor suppressor proteins (e.g., p53. BRCA1) and RNAs, from the nucleus to the cytoplasm. Overexpression of XPO1 is observed in various cancers, where it disrupts normal cellular regulation by sequestering tumor suppressors in the cytoplasm, enabling uncontrolled cell proliferation and survival. Targeting XPO1 has emerged as a promising therapeutic strategy to restore nuclear localization of these proteins and reactivate their antitumor functions.

XPO1 inhibitors, including small molecules and antibodies, block the nuclear export signal (NES) binding site of XPO1. preventing cargo protein export. While small-molecule inhibitors like selinexor (FDA-approved for multiple myeloma and lymphoma) have shown clinical efficacy, their use is limited by toxicity and resistance. Antibody-based approaches aim to improve specificity and reduce off-target effects. Recent advances include the development of anti-XPO1 monoclonal antibodies that selectively bind to XPO1. inhibiting its interaction with cargo proteins or promoting its degradation via immune-mediated mechanisms. Preclinical studies highlight their potential in solid tumors and hematologic malignancies, either as monotherapy or in combination with chemotherapy or targeted therapies. Research continues to optimize antibody design for enhanced pharmacokinetics and tumor penetration. XPO1 antibodies represent a novel class of anticancer agents with broad applicability across diverse malignancies.